Predictive Oncology Inc./$POAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Ticker
$POAI
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
24
ISIN
US74039M3097
Website
POAI Metrics
BasicAdvanced
$8M
-
-$1.75
1.20
-
Price and volume
Market cap
$8M
Beta
1.2
52-week high
$2.60
52-week low
$0.85
Average daily volume
191K
Financial strength
Current ratio
0.756
Quick ratio
0.683
Long term debt to equity
-963.678
Total debt to equity
-1,315.732
Interest coverage (TTM)
-633.30%
Profitability
EBITDA (TTM)
-9.484
Gross margin (TTM)
50.91%
Net profit margin (TTM)
-629.65%
Operating margin (TTM)
-557.71%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-73.20%
Return on equity (TTM)
-490.37%
Valuation
Price to revenue (TTM)
3.24
Price to book
-54.84
Price to tangible book (TTM)
-40.93
Price to free cash flow (TTM)
-0.602
Free cash flow yield (TTM)
-166.02%
Free cash flow per share (TTM)
-149.41%
Growth
Revenue change (TTM)
24.17%
Earnings per share change (TTM)
-52.24%
3-year revenue growth (CAGR)
5.93%
10-year revenue growth (CAGR)
5.29%
3-year earnings per share growth (CAGR)
-34.25%
POAI News
AllArticlesVideos
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
GlobeNewsWire·1 week ago
Court Denies Renovaro Motion for an Expedited Trial in July
GlobeNewsWire·4 weeks ago
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Predictive Oncology Inc. stock?
Predictive Oncology Inc. (POAI) has a market cap of $8M as of June 21, 2025.
What is the P/E ratio for Predictive Oncology Inc. stock?
The price to earnings (P/E) ratio for Predictive Oncology Inc. (POAI) stock is 0 as of June 21, 2025.
Does Predictive Oncology Inc. stock pay dividends?
No, Predictive Oncology Inc. (POAI) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Predictive Oncology Inc. dividend payment date?
Predictive Oncology Inc. (POAI) stock does not pay dividends to its shareholders.
What is the beta indicator for Predictive Oncology Inc.?
Predictive Oncology Inc. (POAI) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.